Leveraging CTCs for Innovative Delivery of FVIII

Microspheres

Next-Generation BAJECT Device

New Formulations

Reconstitution and delivery in one device

Reduce vascular stress and pain

FVIII Microspheres Retain 100% activity

Dry Powder

Oral or Nasal Delivery

Further Enhances Competitive Advantage by Combining Science and Engineering to Create Unique Hemophilia Drug Delivery Systems

Previous slide

Next slide

Back to first slide

View graphic version